Medicines and vaccines are powerful enablers which help people lead longer, healthier and more productive lives. The HIV-related deaths have diminished by more than 80% since 1980. Cancer mortality rates have been reduced by 20% since 1990. Recent pharmaceutical advances have shown that 90% of patients with Hepatitis C can be treated using a 12-week treatment regime.
95% of 15 million European patients with Hepatitis C heal after 8 to 12 weeks of treatment.
Between years 2000 and 2012, the rate of cardiovascular deaths has decreased by 37% in the developed countries of Europe.
New therapies developed between years 2000 and 2012 have helped reduce diabetes deaths by 48% in Korea and 31% in China.
Since 1991, deaths from all cancer types have been reduced by 21%.
Since 1991, the age-standardized mortality rates of HIV patients in France have decreased by 94%.
Exciting impact of more than 7000 innovative medicines currently in development will play a key role in addressing the difficulties experienced by patients and healthcare providers.
We acknowledge the concerns surrounding affordability of innovative medicines and purchasing power issues facing healthcare systems which are under pressure from growing demand for healthcare. The pharmaceutical industry is committed to becoming a part of the solution in supporting greater access and sustainability of healthcare services.
We share a common goal with all healthcare stakeholders: achieving rapid patient access to newest, effective, life-saving medicines. Therefore, and recognizing the future position of innovative medicines, we are working with governments and healthcare providers to help enable better access to medicines and enhanced sustainability of healthcare services.
We are confident that we will be able to develop new pricing models based on results- or value-based agreements, helping to build sustainable healthcare services. These are the initial steps and achieving true innovation entails partnership between patients, healthcare providers, taxpayers and the pharmaceutical industry.